

2023071130031

ÅRSREDOVISNING

för

Recipharm Venture Fund AB

Org.nr. 556666-2697

Styrelsen får härmed avlämna årsredovisning för räkenskapsåret 2022-01-01 - 2022-12-31

Innehåll	Sida
- förvaltningsberättelse	2
- resultaträkning	4
- balansräkning	5
- noter	7
- underskrifter	8

I hereby certify that this is
a true copy of the original

Carl Byström

2023-07-07

076 109 4118



Recipharm Venture Fund AB

Org.nr. 556666-2697

FÖRVALTNINGSBERÄTTELSE

Årsredovisningen är upprättad i svenska kronor, SEK.

Verksamheten**Allmänt om verksamheten**

Recipharm venture Fund AB ska bedriva utveckling, tillverkning och försäljning av läkemedel, naturläkemedel, kosttillskott, medicinska hjälpmedel samt därmed förenlig verksamhet. Vidare ska bolaget styra och sälja utvecklingstjänster inom koncernen samt utveckla immateriella, finansiella och liknande rättigheter inom denna bransch och närliggande branscher.

Under året har bolaget inte haft anställd personal.

Bolaget har sitt säte i Stockholm.

From räkenskapsåret 2022 har bolaget valt att inte ha revisor-

Väsentliga händelser under räkenskapsåret

Bolaget har under året köpt 217 aktier i Sobrera Pharma AB.

Bolaget har under året avyttrat ett aktier i fem bolag:

- 696 500 aktier i Isofol Medical AB
- 251 838 aktier i Xspray Pharma AB
- 38 635 aktier i Lidds AB
- 1 000 aktier i Cinclus Pharma AB
- 4 360 594 aktier i Coegin Pharma AB (Detta skedde efter att bolagets aktier i Follicum AB omvandlades till Coegin Pharma AB vid en fusion)

Flerårsöversikt

Beloppen i Flerårsöversikt visas i KSEK

	2022	2021	2020	2019
Nettoomsättning	0	0	13	2 274
Resultat efter finansiella poster	-6 282	27 870	3 055	16 439
Soliditet i %	99,97	54,24	69,40	11,91
Balansomslutning	26 867	60 980	47 743	278 332
Avkastning på sysselsatt kapital %	-14,27	51,36	9,60	49,66

Definitioner av nyckeltal,

Sysselsatt kapital= Total balansomslutning minus kortfristiga icke räntebärande skulder

Avkastning på sysselsatt kapital= rörelseresultat plus ränteintäkter i förhållande till sysselsatt kapital

Soliditet= eget kapital i förhållande till balansomslutningen

Recipharm Venture Fund AB

Org.nr. 556666-2697

Förändringar i eget kapital

	Aktiekapital	Fri överkursfond	Balanserat resultat	Årets resultat	Summa eget kapital
Belopp vid årets ingång	400 000	651 879 000	-619 168 667	-35 111	33 075 222
Balanseras i ny räkning		0	-35 111	35 111	0
Årets resultat				-6 214 225	-6 214 225
Belopp vid årets utgång	400 000	651 879 000	-619 203 778	-6 214 225	26 860 997

202307130033

Resultatdisposition

Medel att disponera:

Balanserat resultat	-619 203 778
Fri överkursfond	651 879 000
Årets resultat	-6 214 225
	26 460 997

Förslag till disposition:

Balanseras i ny räkning	26 460 997
	26 460 997

Beträffande bolagets resultat och ställning i övrigt hänvisas till efterföljande resultat- och balansräkningar med tillhörande noter.

Recipharm Venture Fund AB

Org.nr. 556666-2697

RESULTATRÄKNING

	Not	2022-01-01 2022-12-31	2021-01-01 2021-12-31
Rörelseintäkter, lagerförändringar m.m.			
Nettoomsättning		0	0
Övriga rörelseintäkter		0	171
Summa rörelseintäkter, lagerförändringar m.m.		0	171
Rörelsekostnader	2		
Övriga externa kostnader		-329 048	-211 692
Övriga rörelsekostnader		-894	-1 861
Summa rörelsekostnader		-329 942	-213 553
Rörelseresultat		-329 942	-213 382
Finansiella poster			
Resultat från övriga finansiella anläggningstillgångar	3	-6 000 413	28 110 857
Övriga ränteintäkter och liknande resultatposter		58 419	23 253
Övriga finansiella kostnader		-163	0
Räntekostnader från koncernföretag		-9 466	-50 747
Summa finansiella poster		-5 951 623	28 083 363
Resultat efter finansiella poster		-6 281 565	27 869 981
Bokslutsdispositioner			
Lämnade koncernbidrag		0	-27 905 092
Summa bokslutsdispositioner		0	-27 905 092
Resultat före skatt		-6 281 565	-35 111
Skatter			
Skatt på årets resultat		67 340	0
Årets resultat		-6 214 225	-35 111

2023071130034

Recipharm Venture Fund AB

Org.nr. 556666-2697

BALANSRÄKNING**TILLGÅNGAR****Anläggningstillgångar****Immateriella anläggningstillgångar**

Produkträttigheter

Not

2022-12-31

2021-12-31

Summa immateriella anläggningstillgångar

4

2 585 550

2 585 550

2 585 550

2 585 550

Finansiella anläggningstillgångar

Andelar i koncernföretag

5

1 087

1 250

Andra långfristiga värdepappersinnehav

16 567 364

40 404 611

Uppskjuten skattefordran

67 340

0

Summa finansiella anläggningstillgångar

16 635 791

40 405 861

Summa anläggningstillgångar

19 221 341

42 991 411

Omsättningstillgångar**Kortfristiga fordringar**

Fordringar hos koncernföretag

7 644 663

17 699 350

Övriga fordringar

565

564

Summa kortfristiga fordringar

7 645 228

17 699 914

Kassa och bank

Kassa och bank

0

288 989

Summa kassa och bank

0

288 989

Summa omsättningstillgångar

7 645 228

17 988 903

SUMMA TILLGÅNGAR**26 866 569****60 980 314**

2023071130035

Recipharm Venture Fund AB

Org.nr. 556666-2697

BALANSRÄKNING

	2022-12-31	2021-12-31
--	------------	------------

EGET KAPITAL OCH SKULDER**Eget kapital****Bundet eget kapital**

Aktiekapital

400 000

400 000

Summa bundet eget kapital

400 000

400 000

Fritt eget kapital

Fri överkursfond

651 879 000

651 879 000

Balanserat resultat

-619 203 778

-619 168 667

Årets resultat

-6 214 225

-35 111

Summa fritt eget kapital

26 460 997

32 675 222

Summa eget kapital

26 860 997

33 075 222

Kortfristiga skulder

Skulder till koncernföretag

0

27 905 092

Övriga skulder

5 572

0

Summa kortfristiga skulder

5 572

27 905 092

SUMMA EGET KAPITAL OCH SKULDER

26 866 569

60 980 314

202307130036

Recipharm Venture Fund AB

Org.nr. 556666-2697

NOTER**Not 1 Redovisnings- och värderingsprinciper**

Årsredovisningen är upprättad i enlighet med årsredovisningslagen och Bokföringsnämndens allmänna råd (BFNAR 2016:10) om årsredovisning i mindre företag.

Tillgångar och skulder har värderats till anskaffningsvärde om inte annat anges.

Fordringar har tagits upp till det belopp varmed de beräknas inflyta.

Koncernbidrag redovisas som Bokslutsdisposition.

Not 2 Rörelsekostnader **2022** **2021**

Rörelsekostnader ingår med följande belopp i nedanstående poster;

Övr försäljningskostnader	-128 449	0
Förvaltningskostnader	-878	-799
Forskningskostnader	-198 120	-192 693
Övr kostnader	-1 763	-18 200
Valutakursförlust	-894	-1 861
	-330 104	-213 553

Not 3 Resultat från övriga finansiella anläggningstillgångar **2022** **2021**

Vinst/förlust försäljning aktier	-6 000 413	28 110 857
----------------------------------	------------	------------

Bolaget har sålt aktier i Isofol Medical AB, Xspay Pharma AB, Lidds AB, Cinclus Pharma AB, Coegin Pharma AB

Not 4 Produkträttigheter **2022-12-31** **2021-12-31**

Ingående anskaffningsvärden	2 585 550	2 585 550
Utgående anskaffningsvärden	2 585 550	2 585 550
Redovisat värde	2 585 550	2 585 550

Investering i ett konsortium som förfogar äganderätten till några produktutvecklingsprojekt.

Rättigheterna består av fyra olika produktutvecklingsprojekt. Projekten befinner sig på ett mycket tidigt stadium.

Not 5 Andelar i koncernföretag **2022-12-31** **2021-12-31**

Företag	Antal /Kapitalandel %	Redovisat värde	Redovisat värde
Organisationsnummer Säte			
1 Aktie i Recipharm Monts SAS	1	163	163
1 Aktie i Recipharm Fontaine SAS		0	163
2 Aktier i Recipharm Pessac SAS	2	924	924
		1 087	1 250

Recipharm Venture Fund AB

Org.nr. 556666-2697

NOTER

Övriga noter

Not 6 Ställda säkerheter och eventutförpliktelser

2022-12-31

2021-12-31

Bolaget har inga ställda säkerheter eller eventutförpliktelser.

Not 7 Väsentliga händelser efter räkenskapsårets slut

Inga väsentliga händelser har inträffat efter räkenskapsårets slut.

Not 8 Koncernförhållanden

Bolaget är helägt dotterbolag till Recipharm AB, Orgnr 556498-8425, med säte i Stockholm. Övergripande koncernredovisning upprättas av Roar HoldCo, 559283-6950, med säte i Stockholm.

DocuSigned by:

Valur Sveinbjörnsson

37CE23E3A85E4E2...
Valur Sveinbjörnsson
Styrelseledamot

DocuSigned by:

Torkel Gren

24E2C81338404DE...
Carl Olof Torkel Gren
Styrelseledamot

DocuSigned by:

Johanna Kvist

EF9E871A8EC04DC...
Johanna Mirjam Kvist
Styrelseledamot

DocuSigned by:

Lisa Lodge

40A0ABE85A8497...
Lisa Lodge
Styrelseledamot

2023071130038

Certificate Of Completion

Envelope Id: B402D92C3B7448819D784DF1613AAA5F
Subject: Complete with DocuSign: Årsredovisning RVF 2023_Final clean.pdf
Source Envelope:
Document Pages: 8 Signatures: 4
Certificate Pages: 5 Initials: 0
AutoNav: Enabled
Envelopeld Stamping: Enabled
Time Zone: (UTC+01:00) Amsterdam, Berlin, Bern, Rome, Stockholm, Vienna

Status: Completed

Envelope Originator:
Natasha Viitasaari
Drottninggatan 29
Stockholm, Stockholm 111 51
natasha.viitasaari@recipharm.com
IP Address: 89.181.47.238

Record Tracking

Status: Original
6/27/2023 1:01:27 PM
Holder: Natasha Viitasaari
natasha.viitasaari@recipharm.com

Location: DocuSign

Signer Events

Johanna Kvist
johanna.kvist@recipharm.com
Global Process lead of Finance
Recipharm
Security Level: Email, Account Authentication
(None), Authentication

Signature

DocuSigned by:
Johanna Kvist
EF0E871A6EC04DC...

Signature Adoption: Pre-selected Style
Using IP Address: 80.76.144.70

Timestamp

Sent: 6/27/2023 8:02:32 PM
Viewed: 6/28/2023 8:03:44 AM
Signed: 6/28/2023 8:03:51 AM

Authentication Details

SMS Auth:
Transaction: 5b05a336-0ebd-441c-826d-ed3edab140d1
Result: passed
Vendor ID: TeleSign
Type: SMSAuth
Performed: 6/28/2023 8:03:36 AM
Phone: +46 73 967 50 78

Electronic Record and Signature Disclosure:
Not Offered via DocuSign

Lisa Lodge
lisa.lodge@recipharm.com
Head of Group Finance
Recipharm
Security Level: Email, Account Authentication
(None), Authentication

DocuSigned by:
Lisa Lodge
40A0ABE859A6497..

Signature Adoption: Pre-selected Style
Using IP Address: 82.18.246.186
Signed using mobile

Sent: 6/27/2023 8:02:31 PM
Resent: 6/28/2023 10:32:03 AM
Viewed: 6/28/2023 1:55:42 PM
Signed: 6/28/2023 1:59:06 PM

Authentication Details

SMS Auth:
Transaction: b4d5727d-42c9-4ec6-9d9d-c113d65ddfc5
Result: passed
Vendor ID: TeleSign
Type: SMSAuth
Performed: 6/27/2023 9:14:02 PM
Phone: +44 7841 978473

Electronic Record and Signature Disclosure:
Not Offered via DocuSign

Torkel Gren
torkel.gren@recipharm.com
Deputy Board Director, Recipharm Venture Fund AB
Security Level: Email, Account Authentication
(None), Authentication

DocuSigned by:
Torkel Gren
24E2C91336404DE...

Signature Adoption: Pre-selected Style
Using IP Address: 90.129.211.50

Sent: 6/27/2023 8:02:31 PM
Resent: 6/28/2023 10:32:03 AM
Viewed: 6/28/2023 4:56:52 PM
Signed: 6/28/2023 4:58:47 PM

Authentication Details

202307130039

202307130040

Signer Events

Signature

Timestamp

SMS Auth:

Transaction: 5bc5db0e-a4c7-43fc-976d-2eef165ef502
Result: passed
Vendor ID: TeleSign
Type: SMSAuth
Performed: 6/28/2023 4:56:45 PM
Phone: +46 73 962 29 60

Electronic Record and Signature Disclosure:

Accepted: 1/4/2022 10:52:02 AM
ID: 97d6297a-a4a0-4059-9d03-e8c736f5f1a4

Valur Sveinbjörnsson
valur.sveinbjornsson@recipharm.com
Head of Treasury
Recipharm
Security Level: Email, Account Authentication (None), Authentication

DocuSigned by:
Valur Sveinbjörnsson
37CE23E3A85E4E2...

Signature Adoption: Pre-selected Style
Using IP Address: 83.185.44.154
Signed using mobile

Sent: 6/27/2023 8:02:32 PM
Resent: 6/28/2023 10:32:04 AM
Viewed: 6/28/2023 10:43:35 AM
Signed: 6/28/2023 10:44:10 AM

Authentication Details

SMS Auth:

Transaction: 821194cb-3892-43e2-8dc7-361375a2744e
Result: passed
Vendor ID: TeleSign
Type: SMSAuth
Performed: 6/28/2023 10:43:27 AM
Phone: +46 73 866 98 34

SMS Auth:

Transaction: e40088c7-dcdf-4e8d-a1ad-31d9e1a23770
Result: passed
Vendor ID: TeleSign
Type: SMSAuth
Performed: 6/29/2023 8:26:15 AM
Phone: +46 73 866 98 34

Electronic Record and Signature Disclosure:

Not Offered via DocuSign

In Person Signer Events

Signature

Timestamp

Editor Delivery Events

Status

Timestamp

Agent Delivery Events

Status

Timestamp

Intermediary Delivery Events

Status

Timestamp

Certified Delivery Events

Status

Timestamp

Carbon Copy Events

Status

Timestamp

Witness Events

Signature

Timestamp

Notary Events

Signature

Timestamp

Envelope Summary Events

Status

Timestamps

Envelope Sent Hashed/Encrypted
Certified Delivered Security Checked
Signing Complete Security Checked
Completed Security Checked

6/27/2023 8:02:32 PM
6/28/2023 10:43:35 AM
6/28/2023 10:44:10 AM
6/28/2023 4:58:47 PM

Payment Events

Status

Timestamps

Electronic Record and Signature Disclosure

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Recipharm AB (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

2023071130042

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Recipharm AB:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: robert.siden@recipharm.com

To advise Recipharm AB of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at robert.siden@recipharm.com and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Recipharm AB

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to robert.siden@recipharm.com and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Recipharm AB

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;

ii. send us an email to robert.siden@recipharm.com and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Recipharm AB as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Recipharm AB during the course of your relationship with Recipharm AB.

Fastställelseintyg till årsredovisning


Intyg om att balansräkningen och resultaträkningen har fastställts

Certification that the balance sheet and income statement have been adopted

Undertecknad styrelseledamot i Recipharm Venture Fund AB, org.nr 556666-2697, intygar, dels att denna kopia av årsredovisningen stämmer överens med originalet, dels att resultaträkningen och balansräkningen har fastställts på årsstämman den 30 juni 2023. Årsstämman beslutade att godkänna styrelsens förslag till hur resultatet ska disponeras.

The undersigned board member of Recipharm Venture Fund AB, reg. no. 556666-2697, hereby certifies that this copy of the annual report conforms to the original and that the income statement and balance sheet were adopted on 30 June 2023. The annual general meeting resolved to adopt the board's proposal regarding the allocation of the company's profits.

Datum / Date: 30 June 2023



Johanna Kvist